RGEN · Repligen Corporation

Repligen Corporation reported strong Q1 FY2026 results, with revenue of $194.3 million up 14.8% from $169.2 million in the prior year quarter. This growth stems from higher product sales in our bioprocessing portfolio, serving large biopharmaceutical companies, CDMOs, and life sciences integrators facing intensifying production cost, capacity, quality, and time pressures in the expanding biologics market.

Gross profit reached $108.3 million, a 19.3% increase from $90.8 million, expanding the gross margin to 55.7%. Management attributes this to higher product sales volumes, a favorable product mix, and improved leverage on indirect labor and overhead costs. While cost of goods sold rose with sales volume, these efficiencies partially offset the increase, enhancing overall profitability.

Operating income jumped 142.3% to $15.9 million (8.2% of revenue) from $6.6 million, showcasing significant operating leverage. The primary driver of higher SG&A expenses was investment in personnel costs from increased headcount to support ongoing growth. These investments align with expectations for rising operating expenses as the company expands its bioprocessing business, balancing growth opportunities with disciplined cost management.

Net income advanced 42.9% to $8.3 million, with diluted EPS rising 50% to $0.15 from $0.10. This resilience underscores the benefits of revenue momentum and margin expansion outweighing growth-related expenses.

Cash generation remained a highlight, with net cash from operating activities doubling to $28.3 million from $15.0 million. After $4.7 million in capital expenditures—supporting bioprocessing capacity—free cash flow totaled $23.6 million. The company continues to finance operations primarily through product sales revenues, maintaining liquidity to fund strategic expansion without reliance on external debt or equity beyond historical issuances.

Operationally, management notes rationalization efforts including writing off abandoned equipment from excess production capacity and discontinuing certain product SKUs, signaling streamlining for efficiency. However, broader macro headwinds persist: ongoing cost inflation in raw materials and supply chain components due to geopolitical conflicts, labor shortages, and FX volatility. Recent U.S. Supreme Court decisions on tariffs introduce uncertainty around refunds and future policy, potentially impacting cost structures and supply-chain planning. Despite these pressures, the biologics market tailwinds and focus on organic innovation position Repligen for sustained leadership in bioprocessing.